James Thornton, venture capital investor, discusses Mylan CEO Heather Bresch’s explanation for the pricing of the EpiPen. CNBC Contributor Bill George, former CEO of Medtronic, and Darnisha Harrison, Ennaid Therapeutics CEO, weigh in.

This was originally published on 8/25/16 on CNBC.